Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
137 hedge funds and large institutions have $1.37B invested in Sage Therapeutics in 2015 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 53 increasing their positions, 41 reducing their positions, and 23 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 41
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
19% more capital invested
Capital invested by funds: $1.15B → $1.37B (+$217M)
17% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 23
2% more funds holding
Funds holding: 134 → 137 (+3)
25% less call options, than puts
Call options by funds: $5.22M | Put options by funds: $6.95M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$41.4M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$35.1M |
| 3 |
Millennium Management
New York
|
+$25.7M |
| 4 |
Jennison Associates
New York
|
+$12.6M |
| 5 |
Bank of New York Mellon
New York
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17.3M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$15.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$9.14M |
| 4 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$6.74M |
| 5 |
O
OrbiMed
New York
|
-$6.35M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
151
Virtu KCG Holdings
New York
| – | -$232K | -5,473 | Closed |
|
|
EGM
152
Engineers Gate Manager
New York
| – | -$213K | -5,031 | Closed |
|
153
Group One Trading
Chicago,
Illinois
| – | -$248K | -5,000 | Closed |
|
154
Simplex Trading
Chicago,
Illinois
| – | -$206K | -4,891 | Closed |
|
155
SG Americas Securities
New York
| – | -$144K | -3,409 | Closed |
|
|
TRCT
156
Tower Research Capital (TRC)
New York
| – | -$110K | -2,592 | Closed |
|
|
PAM
157
Paradigm Asset Management
New York
| – | -$38.1K | -900 | Closed |
|
|
AP
158
Atwood & Palmer
Kansas City,
Missouri
| – | -$1K | -18 | Closed |
|
SAGE Hedge Fund Activity: Q4 2015 in Review
137 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2015, worth a combined $1.37B — up 19% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SAGE positions and 23 closed out — a net gain of 4 holders — while 53 added to existing stakes and 41 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $41.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $17.3M.
- 137 institutional investors held Sage Therapeutics (SAGE) as of Q4 2015, up from 134 in Q3 2015.
- Funds reported $1.37B of Sage Therapeutics stock for Q4 2015, up 19% quarter-over-quarter.
- 27 funds opened new Sage Therapeutics positions in Q4 2015 and 23 closed out, a net change of +4 holders.
- The largest Sage Therapeutics buyer in Q4 2015 was Lord, Abbett & Co, an estimated $41.4M added.
- The largest Sage Therapeutics seller in Q4 2015 was T. Rowe Price Associates, an estimated $17.3M sold.
Based on aggregated 13F filings for Q4 2015.